Can Rybelsus cause constipation? Yes, constipation is a recognised side effect of Rybelsus (semaglutide), an oral GLP-1 receptor agonist used to treat type 2 diabetes in the UK. Whilst gastrointestinal symptoms are common with this medication, constipation occurs less frequently than nausea or diarrhoea, affecting between 1 in 10 and 1 in 100 people. The mechanism relates to semaglutide's effect on gastric emptying and gut motility. Most patients find that bowel symptoms improve over time, and several management strategies can help minimise discomfort whilst maintaining effective diabetes control.

Can Rybelsus Cause Constipation?

Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. Whilst constipation is recognised as a potential adverse effect of Rybelsus, it is considerably less common than other gastrointestinal symptoms associated with this medication.

According to the MHRA-approved Summary of Product Characteristics (SmPC), gastrointestinal side effects are the most frequently reported adverse reactions with semaglutide. These include nausea, vomiting, diarrhoea, and abdominal pain. Constipation is classified as a 'common' side effect (affecting between 1 in 10 and 1 in 100 people), though it occurs less frequently than nausea and diarrhoea. The mechanism by which GLP-1 receptor agonists may cause constipation relates to their effect on gastric emptying and gastrointestinal motility. Semaglutide slows gastric emptying, which is part of its therapeutic mechanism for improving glycaemic control and promoting satiety. However, this delayed transit through the digestive system can occasionally result in constipation (defined as fewer than three bowel movements per week and/or hard stools that are difficult to pass).

It is important to note that not everyone taking Rybelsus will experience constipation, and individual responses to the medication vary considerably. The incidence of constipation appears to be dose-dependent, with higher doses (14 mg) potentially associated with a greater likelihood of bowel changes, as noted in clinical trials. Patients should be aware that gastrointestinal symptoms, including constipation, often improve over time as tolerance to the medication develops, typically within the first few weeks to months of treatment.

Managing Constipation While Taking Rybelsus

If you develop constipation whilst taking Rybelsus, there are several evidence-based strategies that can help manage this side effect without necessarily discontinuing your diabetes medication.

Dietary modifications form the cornerstone of constipation management. Increasing dietary fibre intake to 30 grams daily (the UK recommendation for adults) can significantly improve bowel regularity. It's advisable to increase fibre gradually to reduce the risk of bloating. Good sources include:

• Wholegrain cereals, bread, and pasta

• Fresh fruits (particularly prunes, pears, and apples with skin)

• Vegetables (especially leafy greens, broccoli, and carrots)

• Pulses such as lentils, chickpeas, and beans

• Nuts and seeds

Adequate hydration is equally important, as fibre requires sufficient fluid to work effectively. Aim for 6–8 glasses (approximately 1.5–2 litres) of water daily, unless you have been advised otherwise by your healthcare team due to other medical conditions.

Regular physical activity stimulates intestinal motility and can help prevent constipation. The NHS recommends at least 150 minutes of moderate-intensity activity weekly, which also supports diabetes management and cardiovascular health.

If lifestyle measures prove insufficient, over-the-counter laxatives may be appropriate. According to NICE Clinical Knowledge Summaries and the BNF, bulk-forming laxatives (such as ispaghula husk) or osmotic laxatives (such as macrogol) are generally considered first-line options and are available from pharmacies. However, you should consult your GP or pharmacist before starting any laxative, particularly if you have other medical conditions or take multiple medications. Stimulant laxatives should typically be reserved for short-term use only.

Following the correct administration instructions for Rybelsus may also help minimise gastrointestinal disturbances. Take Rybelsus once daily on an empty stomach with up to 120 ml of water, swallow the tablet whole, and wait at least 30 minutes before eating, drinking, or taking other oral medicines.

When to Seek Medical Advice About Bowel Changes

Whilst mild constipation can often be managed with self-care measures, certain symptoms warrant prompt medical attention. You should contact your GP or healthcare team if you experience:

• Severe or persistent constipation lasting more than one week despite lifestyle modifications and over-the-counter remedies

• Severe abdominal pain or cramping, particularly if accompanied by bloating or distension

• Blood in your stools or black, tarry stools (melaena)

• Unexplained weight loss in addition to bowel changes

• Nausea and vomiting that prevents you from eating, drinking, or taking your medications

• Complete inability to pass stools or wind (which may indicate bowel obstruction)

• Alternating constipation and diarrhoea with no clear pattern

Seek urgent medical attention (contact NHS 111 or attend A&E) if you develop severe, persistent abdominal pain (possibly radiating to the back) with or without vomiting, as this could indicate pancreatitis, a rare but serious side effect of GLP-1 receptor agonists. If pancreatitis is suspected, you should stop taking Rybelsus immediately and seek medical care. Also seek urgent care if you develop signs of dehydration (dizziness, reduced urination, extreme thirst), or if you suspect bowel obstruction.

It is particularly important to discuss bowel changes with your diabetes team if constipation is significantly affecting your quality of life or diabetes management. Persistent gastrointestinal symptoms may impact your ability to maintain adequate nutrition, which is essential for blood glucose control. Your healthcare provider can assess whether the constipation is definitively related to Rybelsus or whether other factors may be contributing, such as:

• Other medications (certain painkillers, iron supplements, or antacids containing aluminium)

• Diabetic autonomic neuropathy affecting gut motility

• Hypothyroidism or other endocrine disorders

• Dietary factors or inadequate fluid intake

Your GP may perform a clinical assessment and, if necessary, arrange investigations to exclude other causes of constipation before considering medication adjustments.

If you believe you've experienced a side effect from Rybelsus, you can report it through the MHRA Yellow Card scheme, which helps monitor medication safety.

Alternative Treatments and Adjusting Your Medication

If constipation remains problematic despite conservative management strategies, your healthcare team may consider several options to optimise your diabetes treatment whilst minimising gastrointestinal side effects.

Dose adjustment may be appropriate in some cases. Rybelsus is initiated at 3 mg daily for one month, then increased to 7 mg, with a possible further increase to 14 mg if additional glycaemic control is needed. If you develop troublesome constipation at a higher dose, your doctor might consider maintaining you on a lower dose if your diabetes control permits, balancing efficacy against tolerability.

Temporary discontinuation and rechallenge is occasionally considered. Some patients find that stopping Rybelsus briefly (under medical supervision) allows gastrointestinal symptoms to resolve, and reintroduction at a lower dose with more gradual titration may improve tolerance. However, this approach must be carefully managed with close monitoring of blood glucose levels to avoid deterioration in glycaemic control.

Alternative GLP-1 receptor agonists may be explored. Different formulations and molecules within this class have varying side effect profiles. For instance, switching from oral semaglutide (Rybelsus) to injectable semaglutide (Ozempic) or other GLP-1 agonists such as dulaglutide (Trulicity) or liraglutide (Victoza) might be considered, though it's important to note that gastrointestinal effects remain common across the class and individual tolerability varies.

Alternative diabetes medication classes may be considered if GLP-1 agonists prove unsuitable. According to NICE guidance (NG28), treatment options for type 2 diabetes include:

• Metformin (usually first-line therapy)

• Sulfonylureas (such as gliclazide)

• SGLT2 inhibitors (such as dapagliflozin or empagliflozin)

• DPP-4 inhibitors (such as sitagliptin)

• Insulin therapy

• Combination therapies tailored to individual circumstances

Your diabetes team will consider multiple factors when reviewing your treatment, including your HbA1c levels, cardiovascular risk profile, renal function, body weight, and personal preferences. Never stop or adjust Rybelsus without consulting your healthcare provider, as abrupt changes may lead to deterioration in blood glucose control. A collaborative approach between you and your diabetes team ensures that any medication adjustments are made safely whilst maintaining optimal diabetes management.

Frequently Asked Questions